HB4457 creates new restrictions on pharmacy benefits managers (PBMs) in Oklahoma, focused on specialty medications and medically integrated pharmacies tied to a patient’s treating specialty provider. The bill defines key terms such as “medically integrated pharmacy,” “specialty medication,” “specialty provider,” and “patient steering,” and then prohibits PBMs from blocking, disadvantaging, or steering patients away from these pharmacies when they are properly licensed, accredited, and participating in the network. It also bars PBMs from requiring patients to use PBM-owned or PBM-affiliated pharmacies exclusively for specialty drugs, from imposing more burdensome network or reimbursement terms on medically integrated pharmacies, and from using prior authorization, step therapy, or utilization management in ways that interfere with continuity of care or access to clinically appropriate therapy.
The bill also requires PBMs to treat medically integrated pharmacies at least as favorably as PBM-affiliated specialty pharmacies, to publish written network participation and credentialing standards on request, and to decide completed specialty network applications within 30 days with written reasons for any denial and an appeal opportunity. It further allows patients to obtain specialty medications through a specialty provider’s medically integrated pharmacy when the provider is actively managing treatment, while preserving the PBM’s ability to apply uniformly written, clinically based utilization controls and not requiring coverage of drugs that are otherwise excluded by the health plan. The bill requires PBMs to keep records for five years and makes those records available to the Attorney General upon request.
In practical terms, the bill would amend Oklahoma insurance and pharmacy-benefit regulation by creating enforceable standards for PBM conduct and specialty pharmacy network access. It would apply to PBMs, health insurers, network pharmacies, specialty pharmacies, specialty providers, and covered persons, and it would give the Attorney General authority to investigate, subpoena records, promulgate rules, and seek injunctive relief, restitution, disgorgement, civil penalties, attorney fees, and costs. Violations are treated as unfair or deceptive acts under state law.
The overall sentiment reflected in the voting history is strongly supportive and largely noncontroversial in committee and on the House floor, with unanimous or near-unanimous votes at each recorded stage. That pattern suggests broad bipartisan agreement on the bill’s consumer-access and provider-autonomy goals, especially for specialty drug access and anti-steering protections. No committee transcript excerpts were provided, so there is no recorded floor or committee debate to indicate opposition arguments.
The main point of contention implied by the bill’s structure is the balance between PBM cost-management tools and provider/pharmacy access. The bill limits PBM steering, network restrictions, and differential reimbursement practices, which could be viewed by PBMs and insurers as reducing their ability to direct patients to preferred pharmacies or manage specialty-drug costs. Supporters, by contrast, appear to favor protecting medically integrated pharmacies and continuity of care for patients with complex, chronic, or rare conditions.
HB4457 would add a new section to Title 36 of the Oklahoma Statutes governing PBM conduct, specialty pharmacy networks, and patient access to specialty medications. It would prohibit discriminatory network, reimbursement, audit, credentialing, and administrative practices against medically integrated pharmacies, require equal access and written standards, and create a 30-day application review process with appeal rights. The bill also expands Attorney General enforcement authority by classifying violations as unfair or deceptive acts and authorizing investigations, rulemaking, civil actions, and monetary and injunctive remedies.
The bill appears to have broad support based on its unanimous committee and floor votes in the House and unanimous committee vote in the Senate Business & Insurance Committee. The available record suggests the measure is viewed favorably as a consumer- and provider-protection bill aimed at specialty drug access and limiting PBM steering. No recorded testimony or transcript excerpts were provided, so the sentiment can only be inferred from the strong voting pattern and lack of recorded opposition.
The central policy tension is between PBM cost-control and network-management practices on one side and access to medically integrated specialty pharmacies on the other. PBMs may object to limits on preferred-pharmacy steering, reimbursement differentials, audit standards, and utilization management tools, because those practices are commonly used to control costs and direct utilization. Supporters are likely to argue that patients with complex conditions should be able to use the pharmacy integrated with their specialty provider without being forced into PBM-affiliated channels, especially when continuity of care is at stake.